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ABSTRACT
Aim of study: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 
5‑fluorouracil (5‑FU) on colon cancer.
Materials and Methods: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by 
sulforhodamine B (SRB) assay.
Results: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on 
oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and 
HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, 
both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity.
Conclusion: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin 
treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for 
colorectal cancer (CRC) treatment and further studies are required.
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INTRODUCTION
Compounds or designed drugs to hinder specific 
cell pathways and interfere with specific targets 
in the treatment of different diseases and 
conditions other than cancer seems to be 
recognized recently as promising anticancer 
therapeutics. In this regards, the repurposing of 
the antiviral, ribavirin, as well as metformin, a 
clinical valuable drug for diabetes type 2, showed 
recently in cancer therapy some promising 
results in different types of cancers.[1‑4] Ribavirin 
(1‑β‑D‑ribofuranosyl‑1,2,4,‑triazole‑3‑carboxami
de) is a well‑known antiviral agent against several 
deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) viruses with more than 40 years of 
clinical usage.[3,5,6] Ribavirin has been proposed as 
a specific inhibitor of inositide‑5’‑monophosphate 
dehydrogenase (IMPDH), a cellular enzyme 
catalyzing the rate limiting step of de novo 
guanosine‑5’‑triphosphate (GTP) synthesis, and 
a transcription factor.[7] In various animal and 
human tumor types, IMPDH expression and 
activity are markedly elevated; hence, it has been 
associated to transformation and proliferation 
of malignant cells. Guanine nucleotides are 
required for several metabolic and signaling 
pathways and functions of cells.[8] In addition, 
other studies indicate that ribavirin acts as a 
physical mimic of the m7G cap and subsequently 
inhibits the eukaryotic translation initiation 
factor 4E (eIF4E) activity by binding to it and 
interferes cap‑dependent translation. [3] In 
consequences, eIF4E is a rate‑limiting factor 
for cap‑dependent protein synthesis that is 
regulated by the phosphoinositide 3‑kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) 
signaling pathway as well as mitogen‑activated 
protein kinase (MAPK)‑interacting kinase 1 and 
2 (MNK1/2)‑mediated phosphorylation. eIF4E 
is overexpressed in many cancers and has 
been reported to have important roles in the 
development and progression of hematological 
malignancies and to be overexpressed in colorectal 
cancer (CRC).[9]
Metformin is a biguanidine believed to inhibit 
the mitochondrial respiratory chain complex I 
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and to interfere with glucose metabolism by activating liver 
kinase B1 (LKB1)/adenosine monophosphate‑activated protein 
kinase (AMPK) pathway resulting in an inhibitory effect on 
mTOR pathway.[10]
In the present study, we used two drugs commonly used in 
CRC therapy; oxaliplatin and 5‑fluorouracil (5‑FU). Oxaliplatin 
mechanism of action is mediated by the formation of DNA adducts 
and consequently it induces DNA lesions such as intrastrand 
crosslinks by covalently binding the platinum compound to 
guanine residues.[11] Oxaliplatin‑DNA adducts are suggested 
to exert their cytotoxicity by directly inhibiting DNA and RNA 
synthesis and inducing apoptosis.[11] A side effect of oxaliplatin 
is producing reactive oxidative species (ROS) and ROS‑dependent 
endoplasmic reticulum (ER) stress and autophagy.[12] On 
the other hand, 5‑FU is a precursor of deoxythymidine 
triphosphate (dTTP) and uridine thriphosphate (UTP) during 
biogenesis; consequently it interferes with both DNA and RNA 
metabolism affecting DNA repair and DNA or RNA synthesis. 
A side effect of 5‑FU on metabolism is on processes dependent 
on mTOR such as autophagy and ER stress response in colon 
cancer cells.[13] It has been reported that compounds which 
inhibit autophagy or hinder ER stress response can sensitized 
cancer cells to oxaliplatin or 5‑FU.[12‑14]
In this study, we examined the effect of two known metabolic 
stressors compounds, ribavirin and metformin on the 
sensibility to Oxaliplatin and 5‑FU in two commercial CRC cell 
lines as well as the importance of glutaminolisys in these cell 
lines by the use of Compound 968, a well‑known inhibitor of 
mitochondrial glutaminase activity.[15]
There are nonoverlapping side effect profiles of Oxaliplatin 
and 5‑FU on metabolic processes this provide a basis for 
investigating the toxicity of drugs such as ribavirin and 
metformin in combination with the two primary drugs. 
We found synergistic interaction on Oxaliplatin as well as 
differences between the cell lines in the way they use glutamine. 
On the basis of these findings it is required continue with the 
validation in different phenotypic and genetic backgrounds of 
CRC cell lines to support the real use of ribavirin and metformin 
specially on oxaliplatin treatment in CRC.
MATERIALS AND METHODS
Cell culture and reagents: HT29 and HCT116 colon cancer 
cell lines were obtained from the American Type Culture 
Collection and were maintained at 37°C in 5% CO
2
 and 
Roswell Park Memorial Institute medium (RPMI) with 
10% fetal bovine serum (Cat # 11875093, Invitrogen, 
Argentina) and gentamicin (40 μg/ml, Invitrogen, Argentina 
Cat # 15750078). The chemicals and reagents obtained from 
Sigma‑Aldrich, Buenos Aires, Argentina were: ribavirin (Cat. 
R9644, 10 mg); metformin (Cat. 53183‑1,1‑dimethylbiguanide 
hydrochloride); oxaliplatin (Cat. O9512, 5 mg), and 5‑FU 
(Cat. F6627, 1 g).
Sulforhodamine B (SRB) cytotoxicity assays: SRB assays were 
performed according to the method of.[16] Briefly, cells were 
seeded at low density in wells of a 96‑well plate (final density 
of 80% of confluency in wells of nontreated cells in a 96‑well 
plate) and after 24 h incubation they were subsequently treated 
with oxaliplatin or 5‑FU alone, ribavirin or metformin alone, 
and in combination with oxaliplatin or 5‑FU. After three double 
time post drug treatment, cells were fixed with trichloroacetic 
acid, stained with SRB (Sigma Aldrich, Argentina, Cat. S1402), 
and analyzed for percent of survival on a 96‑well plate reader. 
Efficacies of the various drug treatments were determined by 
calculating 50% inhibitory concentrations (IC
50
) and synergy 
values. Synergy values were calculated using the ratio of 
IC
50
 of primary drug alone (oxaliplatin or 5‑FU) divided by 
combination IC
50
s as previously used.[4] Using this equation, 
R values more than 1.6 were indicative of synergy, equal to 
1 indicate additive behavior, and less than 1 indicate inhibitory 
drug interactions.
Analysis
There were at least five replicates for all SRB experiments. 
Means were calculated and then compared employing the 
Student’s t‑test analysis (P < 0.05) using SigmaStat software.
RESULTS
We obtained the 50% inhibitory concentrations, IC
50
, for all 
the drugs used in this study [Table 1]. Both cell lines showed 
no significant different values for IC
50
 with the exception of 
fivefold significantly different response to a mitochondrial 
glutaminase activity inhibitor, Compound 968. HT29 cell 
line showed to be more resistant (17.5 μM ± 3) than 
HCT116 (3.6 μM ± 2.4); suggesting that they have different 
metabolic requirements of glutamine which can be exploited 
for future studies (P < 0.05) [Table 1].
Our study of drug combination showed that a clinically 
achievable concentration of ribavirin (10μM), which was not 
cytotoxic to the cells in culture, resulted in a significantly 
synergistic effect on oxaliplatin in both cell lines tested 
with the sensitization index (R) of 2.93 ± 0.3 for HT29 and 
1.71 ± 0.2 for HCT116, respectively (IC
50
 [Figure 1] and 
P < 0.001 [Table 1]);  while ribavirin did not affect the response 
to 5‑FU. Metformin sensitized significantly HT29 cell line to 
oxaliplatin (R = 2.66 ± 0.28), while it did not show synergy 
in HCT116 or in combination with 5‑FU in both the cell lines 
[Table 1].
Interestingly, Compound 968 showed a differential effect alone 
between cell lines [Table 1], though neither did it sensitize 
HT29 nor HCT116 to oxaliplatin or to 5‑FU (data not shown).
DISCUSSION
Genomic studies reported that PI3K/AKT pathway is highly 
deregulated in CRC.[17] AKT activates downstream mTOR, 
[Downloaded free from http://www.cancerjournal.net on Monday, July 30, 2018, IP: 168.96.240.2]
Richard and Marignac: Metformin and ribavirin synergized to oxaliplatin in CRC
338 Journal of Cancer Research and Therapeutics - April-June 2015 - Volume 11 - Issue 2
a serine/threonine kinase that can be found in two types of 
complex mTorc1 and mTorc2. In tumorigenic development 
and cancer progression, mTorc1 is critical[18] as well as it is 
deregulated. mTorc1 is also involved in the activation of 
eIF4E and eIF4E recognition of mRNA 5’cap important in the 
regulation of translation in eukaryotes.[4] In cancer and CRC 
as mTorc1 is deregulated, eIF4E is generally upregulated.[9] 
In consequences, ribavirin as an inhibitor of cap‑dependent 
translation would target naturally a pathway that is 
overexpressed in CRC cells.[9] Our results showed that this 
pathway seems to become essential only in both cell lines, 
HT29 and HCT116, after the treatment with oxaliplatin 
and not with 5‑FU. It is inferred that CRC cells turn to 
cap‑dependent translation after Oxaliplatin treatment as we 
found a significant synergy resulted in combined treatment 
with ribavirin. In summary, the data suggest that at low dose 
ribavirin combined treatment with oxaliplatin can be an 
effective therapeutic approach for CRC, which needs further 
testing.
On the other hand, in animal studies metformin have shown 
to inhibit the proliferation of colon epithelium as well as the 
aberrant crypt foci;[18‑21] summing up metformin seems to 
inhibit tumors growth in colon of animal models.[18,19] Here, 
Table 1: IC50 in HT29 and HCT116
HT29 IC50 HCT116 IC50
Ribavirin 38.6 μM±1.1 Ribavirin 27.5 μM±1.8
Metformin 5.9 mM±0.09 Metformin 6.5 mM±1,7
Comp968 17.5 μM±3.6 Comp968 3.6 μM±2.4
Oxaliplatin 0.88 μM±0.2 Oxaliplatin 0.41 μM±0.02 μM±0.01
5‑FU 4.20 μM±0.3 5‑FU 3.30 μM±0.6
HT29 IC50 R HCT116 IC50 R
Oxaliplatin Oxaliplatin
Plus 5 μM ribavirin 0.30 μM±0.01* R=2.93, P<0.001 Plus 5 μM ribavirin 0.24 μM±0.02* R=1.71, P<0.001
Plus 1 mM metformin 0.33 μM±0.02* R=2.66, P<0.010 Plus 1 mM metformin 0.37 μM±0.1 R=1.6, P>0.05
5‑FU 5‑FU
Plus 5μM ribavirin 4.7 μM±0.7 Plus 5 μM ribavirin 2.8 μM±0.7
Plus 1 mM metformin 4.5 μM±0.5 Plus 1 mM metformin 2.4 μM±0.6
*Significant synergy. IC50=50% inhibitory concentration, 5‑FU=5‑fluorouracil. Top part of the table shows. IC50 concentrations for the drug individually; and the 
second part shows IC50 for different combinations for each of the primary drugs, oxaliplatin and 5‑FU plus ribavirin and metformin with their corresponding R values
Figure 1: Survival curves and histogram showing IC50. (a) Metformin and ribavirin Neither Metformin nor ribavirin showed synergy with 5-FU in 
HT29 or HCT116 when combined in nontoxic concentrations when combined in nontoxic concentrations. Metformin and ribavirin significantly 
sensitized HT29 to oxaliplatin and only ribavirin synergized with oxaliplatin in HCT116 cell line. (b) HT29 and HCT116 differed significantly in 
their response to Compound 968 (P < 0.05). IC50 = 50% inhibitory concentration, 5‑FU = 5‑fluorouracil
b
a
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metformin significantly synergized with oxaliplatin only in 
HT29 cell line, suggesting that cell response to oxaliplatin 
treatment rely more on mTOR, and downstream of PI3K/AKT, 
as well as on mitochondrial complex I and AMPK, in a 
heterogeneous genetic or metabolic manner.[22]
Regarding the heterogeneous genetic and metabolic baseline 
between the two cell lines analyzed here, we reported that 
HCT116 on the contrary to HT29 depends on glutamine 
metabolism as Compound 968 showed to be more toxic in 
this cell line. Previously other reports also suggested that 
the commercial CRC cell lines show differences in the use 
of nutrients and the metabolic process which sustain their 
survival in vitro and in response to stressors.[23,24] Furthermore, 
though we showed basal differences between HT29 and HCT116 
in how they responded to Compound 968; Compound 968 did 
not show synergy to oxaliplatin or 5‑FU (data not showed), 
suggesting that nonetheless mitochondrial glutaminase 
activity is highly active and overexpressed in CRC,[25] the cells 
did not turn to this metabolic pathway for survival after the 
treatments.
Here we showed sensitization to oxaliplatin by blocking the 
cap‑dependent translation using ribavirin and interfering 
mTOR/mitochondrial complex I by the use of metformin. 
These findings suggested that the metabolic changes induced 
by oxaliplatin were dependent on downstream of PI3K/AKT 
pathway,[23] in particular mTOR/eIF4E pathway in HT29 and 
HCT116 cell lines and LKB1/AMPK pathway and mitochondrial 
complex I in HT29.
HT29 and HCT116 are two of the commonly employed colon 
cancer cell lines in research. They differ in their gender origin 
and mutation status, and probably as well in their metabolic 
requirements as expressed above. HT29 have been reported 
to use glucose preferentially through the pentose phosphate 
pathway,[24] while higher metabolic requirement of glutamine 
by HCT116 could be inferred by our and[26] results. In addition, 
HCT116 has mutations in PI3KCA and K‑RAS genes which confer 
constitutive activation of PI3K/AKT and K‑RAS pathways,[27] 
while HT29 has a deficient p53 gene expression.[28] In the 
present work how this can affect the metabolic reorganization 
of these cell line after oxaliplatin treatment could be only 
suggested. While ribavirin showed a synergistic effect 
on oxaliplatin in both cell lines, metformin showed only 
synergistic effect in HT29. Both drugs hind PI3K/AKT pathways; 
however, metformin also activates AMPK, a metabolic stress 
sensor that regulates several downstream effects on metabolic 
adaptation; such effect include AMPK‑dependent activation of 
p53 which stimulates a stress response. It has been reported 
that metformin has a strong effect on p53 deficient cell lines;[29] 
though the scope of the present work was not to elucidate 
the differential mechanism by which HT29 and not HCT116 
respond synergistically to metformin and oxaliplatin, we can 
suggest that the sensitivity to metformin can be accounted 
to deficiency in the AMPK/p53 axis.[29,30]
In summary, our results implied that it is indispensable to 
analyze further the changes undergone by CRC cells and 
described the metabolic pathways they turn to maintain their 
survival and cell homeostasis after oxaliplatin. We suggest that 
such studies could help to predict the mechanism involved in 
developing recurrence and resistance to drugs. Finally, the way 
CRC cells adapt to metabolic stress induced by drugs commonly 
used in CRC treatment may inform the different ways patients 
answer to therapy.
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